27 mg retatrutide/tirzepatide blend overview covering receptor overlap, lack of direct combination evidence, safety limits and batch COA verification.
This research blend combines 12 mg retatrutide with 15 mg tirzepatide. The higher total content does not establish greater suitability, effect or safety.
Both ingredients engage GIP and GLP-1 receptors, and retatrutide also engages glucagon receptors. The exact mixture has not been studied in a controlled clinical trial.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
The combination duplicates incretin pathways rather than creating a clinically validated new mechanism. Receptor diagrams can show overlap, but they cannot predict combined exposure or tolerability.
Dose-response observations from separate trials cannot be added together. Formulation stability and interaction effects are blend-specific questions.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
In Phase 3 TRIUMPH-4 trial data, average weight loss reached 28.7% of body weight at 68 weeks on the 12 mg dose
Trial data suggest increased resting energy expenditure via glucagon receptor activation, distinct from GLP-1-only agonists
Phase 2a sub-study reported liver fat reduction of up to 86% at 12 mg, with 93% of participants reaching normal liver fat levels
Phase 3 T2D trial data show HbA1c reductions of up to 2.0%, with 82% of participants reaching HbA1c ≤6.5% in earlier Phase 2 data
Trial data reported relief from knee osteoarthritis pain and improved physical function scores in a Phase 3 sub-analysis
Trial data show favorable shifts in cardiovascular risk markers: reduced triglycerides, blood pressure, and non-HDL cholesterol
Retatrutide phase 2 results and tirzepatide prescribing information offer component context only. Participants in those sources did not receive this mixture.
What the evidence cannot answer: Because this page covers a high-strength experimental blend, the evidence gap should be more visible—not less visible—than the individual ingredient summaries.
Open the published batch report and match its COA number to the vial used in your research.
View Retatrutide 12 + Tirzepatide 15 COAResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
Quantum publishes an individual report for this entry and keeps the broader lab-results archive available for comparison.
Overlapping incretin exposure can create serious interpretation and tolerability concerns; human-care decisions require an authorized product and qualified prescriber.
Product status: The blend is not an authorized medicine. Authorized tirzepatide evidence does not transfer to Quantum’s combined research vial.
The tracker separates baseline screening, titration decisions, tolerance notes, monthly review and metabolic measurements.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
This research blend combines 12 mg retatrutide with 15 mg tirzepatide. The higher total content does not establish greater suitability, effect or safety.
The combination duplicates incretin pathways rather than creating a clinically validated new mechanism. Receptor diagrams can show overlap, but they cannot predict combined exposure or tolerability.
Retatrutide phase 2 results and tirzepatide prescribing information offer component context only. Participants in those sources did not receive this mixture. No combined pharmacokinetic model, titration schedule, comparative benefit or long-term safety dataset exists for the 12/15 mg blend.
The blend is not an authorized medicine. Authorized tirzepatide evidence does not transfer to Quantum’s combined research vial.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Use the individual batch report to verify identity, analytical method, reported purity and COA number. Match that number to the vial; a general purity claim is not batch verification.